SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 6)

Inventiva S.A.

(Name of Issuer)

Ordinary Shares, nominal value (euro)0.01 per share

(Title of Class of Securities)

46124U107

(CUSIP Number)

JAMES KRATKY
BVF PARTNERS L.P., 44 Montgomery St., 40th Floor
San Francisco, CA, 94104
415-525-8830

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

11/17/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.

46124U107

Name of reporting person

BIOTECHNOLOGY VALUE FUND L P

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 5,654,825.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 5,654,825.00

Aggregate amount beneficially owned by each reporting person

5,654,825.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

2.9 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP No.

46124U107

Name of reporting person

BVF I GP LLC

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 5,654,825.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 5,654,825.00

Aggregate amount beneficially owned by each reporting person

5,654,825.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

2.9 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP No.

46124U107

Name of reporting person

BIOTECHNOLOGY VALUE FUND II LP

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 3,321,861.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 3,321,861.00

Aggregate amount beneficially owned by each reporting person

3,321,861.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

1.7 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP No.

46124U107

Name of reporting person

BVF II GP LLC

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 3,321,861.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 3,321,861.00

Aggregate amount beneficially owned by each reporting person

3,321,861.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

1.7 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP No.

46124U107

Name of reporting person

Biotechnology Value Trading Fund OS LP

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 397,086.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 397,086.00

Aggregate amount beneficially owned by each reporting person

397,086.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

0.2 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP No.

46124U107

Name of reporting person

BVF Partners OS Ltd.

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 397,086.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 397,086.00

Aggregate amount beneficially owned by each reporting person

397,086.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

0.2 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP No.

46124U107

Name of reporting person

BVF GP HOLDINGS LLC

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 8,976,686.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 8,976,686.00

Aggregate amount beneficially owned by each reporting person

8,976,686.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

4.7 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP No.

46124U107

Name of reporting person

BVF PARTNERS L P/IL

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 9,569,863.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 9,569,863.00

Aggregate amount beneficially owned by each reporting person

9,569,863.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

4.99 %

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13D

CUSIP No.

46124U107

Name of reporting person

BVF INC/IL

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 9,569,863.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 9,569,863.00

Aggregate amount beneficially owned by each reporting person

9,569,863.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

4.99 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP No.

46124U107

Name of reporting person

LAMPERT MARK N

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 9,569,863.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 9,569,863.00

Aggregate amount beneficially owned by each reporting person

9,569,863.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

4.99 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

Item 1.

Security and Issuer

(a)

Title of Class of Securities:

Ordinary Shares, nominal value (euro)0.01 per share

(b)

Name of Issuer:

Inventiva S.A.

(c)

Address of Issuer's Principal Executive Offices:

50 RUE DE DIJON, DAIX, FRANCE , 21121.

Item 1 Comment:

This statement relates to the Ordinary Shares, nominal value (euro)0.01 per share (the "Shares"), of Inventiva S.A., a corporation organized under the laws of France (the "Issuer"), and to American Depositary Shares of the Issuer ("ADSs"), each of which represents one Share. This Amendment No. 6 to the Schedule 13D is being filed due to a change in the percentage of the outstanding number of Shares and ADSs owned by the Reporting Persons solely due to an increase in the number of Shares and/or ADSs outstanding.

Item 5.

Interest in Securities of the Issuer

(a)

Item 5(a) is hereby amended and restated to read as follows: The aggregate percentage of Shares reported owned by each person named herein is based on a denominator which is the sum of: (i) 145,951,274 Shares outstanding (including Shares underlying ADSs) as of October 20, 2025, which is the total number of Shares outstanding as reported in the Issuer's Press Release issued on October 20, 2025, and (ii) 44,805,193 ADSs issued following the closing of the Issuer's offering (including the underwriters' full exercise of an option to purchase additional ADSs) as disclosed in Exhibit 99.1 to the Issuer's Report of Foreign Issuer on From 6-K filed with the Securities and Exchange Commission on November 17, 2025.

(b)

Item 5(b) is hereby amended and restated to read as follows: As of the date hereof, the Reporting Persons and the Partners Managed Account held an aggregate of 10,103,703 T2 PFW-BSAs, exercisable into an aggregate of 19,197,036 Shares. As of the date hereof, the T2 PFW Beneficial Ownership Limitation limits the exercise of the T2 PFWs held by the Reporting Persons and the Partners Managed Account to 1,024,364 Shares underlying the T2 PFWs held by them. The Warrants may not be exercised until the Warrant Exercise Event. As of the date hereof, the Reporting Persons and the Partners Managed Account held an aggregate of 8,231,034 T1 BSAs and 1,872,668 T1 bis BSAs, exercisable into an aggregate of 8,231,034 Shares and 1,872,668 Shares, respectively. As of the date hereof, the T1 BSA Beneficial Ownership Limitation and the T1 bis BSA Beneficial Ownership Limitation prohibits the exercise of all of the T1 BSAs and T1 bis BSAs held by the Reporting Persons and the Partners Managed Account. As of the date hereof, (i) BVF beneficially owned 5,654,825 Shares, including 451,003 Shares underlying ADSs and 1,024,364 Shares underlying certain T2 PFWs held by it, and excluding (a) 3,974,936 Shares issuable upon the exercise of the T1 BSAs held by it, (b) 979,028 Shares issuable upon the exercise of the T1 bis BSAs held by it and (c) 9,197,858 Shares issuable upon the exercise of certain T2 PFW-BSAs held by it, representing percentage ownership of approximately 2.9% of the Shares outstanding, (ii) BVF2 beneficially owned 3,321,861 Shares, including 234,997 Shares underlying ADSs and excluding (a) 3,640,567 Shares issuable upon the exercise of the T1 BSAs held by it, (b) 767,394 Shares issuable upon the exercise of the T1 bis BSAs held by it and (c) 7,161,058 Shares issuable upon the exercise of the T2 PFW-BSAs held by it, representing percentage ownership of approximately 1.7% of the Shares outstanding, (iii) Trading Fund OS beneficially owned 397,086 Shares, including 40 Shares underlying ADSs and excluding (a) 470,954 Shares issuable upon the exercise of the T1 BSAs held by it, (b) 105,296 Shares issuable upon the exercise of the T1 bis BSAs held by it and (c) 1,307,094 Shares issuable upon the exercise of the T2 PFW-BSAs held by it, representing percentage ownership of less than 1% of the Shares outstanding, and (iv) 196,091 Shares were held in the Partners Managed Account, excluding (a) 144,577 Shares issuable upon the exercise of the T1 BSAs held in the Partners Managed Account, (b) 20,950 Shares issuable upon the exercise of the T1 bis BSAs held in the Partners Managed Account and (c) 506,662 Shares issuable upon the exercise of the T2 PFW-BSAs held by it, representing percentage ownership of less than 1% of the Shares outstanding. BVF GP, as the general partner of BVF, may be deemed to beneficially own the 5,654,825 Shares beneficially owned by BVF, representing percentage ownership of approximately 2.9% of the Shares outstanding. BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 3,321,861 Shares beneficially owned by BVF2, representing percentage ownership of approximately 1.7% of the Shares outstanding. Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 397,086 Shares beneficially owned by Trading Fund OS, representing percentage ownership of less than 1% of the Shares outstanding. BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 8,976,686 Shares beneficially owned in the aggregate by BVF and BVF2, representing percentage ownership of approximately 4.7% of the Shares outstanding. Partners, as the investment manager of BVF, BVF2, Trading Fund OS and the Partners Managed Account and the sole member of Partners OS, may be deemed to beneficially own the 9,569,863 Shares beneficially owned in the aggregate by BVF, BVF2, Trading Fund OS, and held in the Partners Managed Account, representing percentage ownership of approximately 4.99% of the Shares outstanding. BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 9,569,863 Shares beneficially owned by Partners, representing percentage ownership of approximately 4.99% of the Shares outstanding. Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 9,569,863 Shares beneficially owned by BVF Inc., representing percentage ownership of approximately 4.99% of the Shares outstanding.

(c)

Item 5(c) is hereby amended and restated to read as follows: The Reporting Persons have not entered into any transactions in the securities of the Issuer during the past sixty days.

(e)

As of the close of business on November 17, 2025, the Reporting Persons ceased to beneficially own more than 5% of the outstanding Shares and/or ADSs.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BIOTECHNOLOGY VALUE FUND L P

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	11/19/2025

BVF I GP LLC

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	11/19/2025

BIOTECHNOLOGY VALUE FUND II LP

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	11/19/2025

BVF II GP LLC

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	11/19/2025

Biotechnology Value Trading Fund OS LP

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	11/19/2025

BVF Partners OS Ltd.

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	11/19/2025

BVF GP HOLDINGS LLC

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	11/19/2025

BVF PARTNERS L P/IL

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	11/19/2025

BVF INC/IL

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	11/19/2025

LAMPERT MARK N

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert
Date:	11/19/2025

Amendment: SEC Form SCHEDULE 13D/A filed by Inventiva S.A.